Repligen Corp Community Page | What other sites are saying about Repligen Corp

Repligen Corp

(NQ: RGEN)

7.690 USD -0.230 (-2.90%)

Streaming Delayed Price / Updated: 2:21 PM EDT, Jun 19, 2013 / Add to My Watchlist

(RGEN) Community Analysis from

READ MORE (RGEN)

Bulls REASONS TO BUY

View all Bulls Reasons

Bears REASONS TO SELL

View all Bears Reasons

June 19, 2013

Chart Analysis: RGEN – Speculative Biotech

(, 2/27/11)

Repligen Corp (RGEN) has been settling near the bottom of the trading range on low volume. It has formed a small head and shoulders pattern, but it seems to have relatively good support around...(read more)

Chart Of The Week: Repligen (RGEN), A Promising Biotech Play

(, 1/25/11)

Repligen Corporation (RGEN) is a biopharmaceutical company which engages in the development and commercialization of therapies that deliver value to patients and clinicians in...(read more)

Repligen Announces Completion of Patient Enrollment in Phase 2b Clinical Trial of RG2417

(Benzinga, 9/30/10)

Repligen Corporation (Nasdaq: RGEN) reported today that it has completed enrollment of patients in its Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression. This study is a...(read more)

View all posts about Repligen (RGEN)

Repligen (RGEN) Company Overview

There is no analysis for RGEN yet. But you can go to Wikinvest to help create one!

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates